May 28, 2015
Novocure Announces First Analysis of Full 700 Patient Dataset from Successful Newly Diagnosed GBM Phase III Trial
Full dataset analysis confirms study met its endpoints, extending both progression-free and overall survival of newly diagnosed GBM patients Analysis will be presented on June 2, 2015 by Roger Stupp, MD at the 2015 Meeting of the American Society of Clinical Oncology in Chicago… Read More
learn more
May 28, 2015
Novocure Hosts First Glioblastoma-focused Hackathon to Develop New Support Tools for the GBM Brain Cancer Community
Technology experts and cancer patient advocates will #HackGBM in Chicago this week May 28, 2015 03:59 PM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, today kicks off Hack GBM: Finding Support Solutions for Glioblastoma Community Challenges, the first-ever hackathon to specifically… Read More
learn more
May 27, 2015
Novocure Announces Commercial Launch of Optune (the NovoTTF-100A System) in Japan
Optune, a Tumor Treating Fields delivery system, provides a novel, non-invasive treatment for recurrent glioblastoma, the most common malignant primary brain cancer Physicians at 23 brain cancer centers in Japan are now certified to provide Optune to recurrent glioblastoma patients on prescription order May… Read More
learn more
May 13, 2015
Novocure to Present New Clinical and Preclinical Data on Tumor Treating Fields at the American Society of Clinical Oncology Annual Meeting 2015
Presentation by Roger Stupp, MD will be the first report on the full 700 patient population that enrolled to the EF-14 trial in newly diagnosed glioblastoma 2015 ASCO Annual Meeting May 13, 2015 05:00 PM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage… Read More
learn more
May 11, 2015
NCCN Guidelines Recommend Tumor Treating Fields as a Standard Treatment Option for Recurrent Glioblastoma
Optune, a Tumor Treating Fields delivery system, provides a non-invasive, low-toxicity, home-use treatment for recurrent glioblastoma, the most common malignant primary brain cancer May 11, 2015 12:18 PM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that Optune has… Read More
learn more
May 11, 2015
FDA Grants Priority Review Status for Novocure’s PMA Supplement Application of Optune in Newly Diagnosed Glioblastoma
PMA Supplement application for Tumor Treating Fields in combination with temozolomide chemotherapy for newly diagnosed glioblastoma accepted for filing and review May 11, 2015 10:54 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that its Premarket Approval (PMA)… Read More
learn more
May 5, 2015
Novocure Kicks Off Brain Tumor Awareness Month with New Activities to Address Challenges in the Glioblastoma Community
Tune-In to GBM initiative will culminate in first GBM Hackathon event to find innovative solutions for patients and caregivers May 05, 2015 08:00 AM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that it is sponsoring its Tune-In to GBM… Read More
learn more
